Urotoxicity of Cyclophosphamide: A Comparison Across Neoplastic, Autoimmune, and Transplant Indications
Author Information
Author(s): Muacevic Alexander, Adler John R, Gu Joyce H, Samarneh Mark
Hypothesis
How does the urotoxicity of cyclophosphamide and ifosfamide compare across different patient populations?
Conclusion
Transplant patients show increased susceptibility to cyclophosphamide urotoxicity compared to other patient groups.
Supporting Evidence
- Transplant patients had a higher risk of bladder toxicity from cyclophosphamide.
- Use of MESNA showed a protective effect against urotoxicity.
- Bladder toxicity reports included various adverse effects like hemorrhagic cystitis and urinary tract infections.
- Statistical analysis revealed significant associations for severe bladder toxicity manifestations.
- Prior studies had limited sample sizes compared to this large-scale analysis.
Takeaway
Cyclophosphamide can hurt the bladder, especially in patients getting transplants, but a medicine called MESNA can help protect against this.
Methodology
A disproportionality analysis using the FAERS database from Q4 2012 to Q2 2024.
Potential Biases
Potential selection bias due to reliance on reported adverse events.
Limitations
The study relies on spontaneous reporting, which may introduce bias and does not capture all adverse events.
Participant Demographics
{"CYC":{"total":197185,"female":96879,"male":64145,"unknown_sex":36161,"age_distribution":{"<18":18784,"18-24":4727,"25-64":80325,"≥65":40742,"unknown_age":52607}},"IFO":{"total":20998,"female":6650,"male":9624,"unknown_sex":4724,"age_distribution":{"<18":4292,"18-24":1313,"25-64":6882,"≥65":1897,"unknown_age":6614}}}
Statistical Information
Confidence Interval
{"CYC":"1.26 [1.23, 1.29]","IFO":"0.95 [0.88, 1.04]"}
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website